O
CCCC icon

OrbiMed’s C4 Therapeutics CCCC Stock Holding History

OrbiMed’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-150,000
Closed -$540K – 112
2024
Q4 		$540K Hold
150,000
– – 0.01% 114
2024
Q3 		$855K Buy
+150,000
New +$903K 0.02% 116

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed's CCCC Position: Q1 2026 in Review

OrbiMed reduced its C4 Therapeutics (CCCC) stake by 39% in Q1 2026, selling an estimated $1.29M and leaving 856,353 shares worth $2.25M. The position accounts for 0.04% of the portfolio, ranked #106.

OrbiMed first reported a position in CCCC in Q2 2024 and has held it in 8 quarters since. The position peaked at $25M in Q3 2024. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • OrbiMed held 856,353 shares of C4 Therapeutics worth $2.25M as of Q1 2026.
  • OrbiMed sold 548,549 C4 Therapeutics shares in Q1 2026, an estimated $1.29M.
  • C4 Therapeutics made up 0.04% of OrbiMed's portfolio in Q1 2026, its #106 holding.
  • OrbiMed first reported a position in C4 Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • OrbiMed's C4 Therapeutics position peaked at $25M in Q3 2024.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.